<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>339</serviceExecutionTime><Drug id="75559"><DrugName>bepotastine salicylate (allergy), Hanlim/ Samchundang/ Dong Kook/ Daewon/ Sam-A</DrugName><DrugNamesKey><Name id="43014538">Belion</Name><Name id="42970291">Berion</Name><Name id="42901975">bepotastine</Name></DrugNamesKey><DrugSynonyms><Name><Value>bepotastine</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>bepotastine salicylate (allergy), Hanlim/ Samchundang/ Dong Kook/ Daewon/ Sam-A</Value></Name><Name><Value>Berion</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>bepotastine salicylate</Value></Name><Name><Value>bepotastine (allergy), Hanlim</Value></Name><Name><Value>Belion</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>125602-71-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1004564">Hanlim Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1004564">Hanlim Pharmaceutical Co Ltd</Company><Company id="23350">Daewon Pharm Co Ltd</Company><Company id="1037556">SamChunDang Pharm Co Ltd</Company><Company id="19561">SAMA Pharm Co Ltd</Company><Company id="21257">Dong Kook Pharmaceutical Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="75559" type="Drug"><TargetEntity id="729021" type="siDrug">Bepotastine salicylate</TargetEntity></SourceEntity><SourceEntity id="1004564" type="Company"><TargetEntity id="5000831397" type="organizationId">Hanlim Pharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1037556" type="Company"><TargetEntity id="4295882328" type="organizationId">Sam Chun Dang Pharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="19561" type="Company"><TargetEntity id="4295882179" type="organizationId">Sam-A Pharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="21257" type="Company"><TargetEntity id="4295882458" type="organizationId">Dongkook Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="23350" type="Company"><TargetEntity id="4295881724" type="organizationId">Daewon Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="12" type="ciIndication"><TargetEntity id="10001708" type="MEDDRA"></TargetEntity><TargetEntity id="1180" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="199" type="Action"><TargetEntity id="196" type="Mechanism">Histamine H1 Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00915" type="ciTarget"><TargetEntity id="19255861332693" type="siTarget">Histamine H1 receptor</TargetEntity><TargetEntity id="-722811295" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Allergy - South Korea - May-2013</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="12">Allergy</Indication></IndicationsPrimary><ActionsPrimary><Action id="199">Histamine H1 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="250">Mast cell degranulation inhibitor</Action><Action id="2953">Anti-inflammatory</Action><Action id="5631">Eosinophil migration inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2013-10-22T10:30:22.000Z</LastModificationDate><ChangeDateLast>2017-07-08T00:00:00.000Z</ChangeDateLast><AddedDate>2012-01-14T04:29:36.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1004564"&gt;Hanlim&lt;/ulink&gt; has developed and launched  &lt;ulink linkType="Drug" linkID="10980"&gt;bepotastine&lt;/ulink&gt; salicylate (Berion; Belion), a histamine H1 antagonist that  inhibits mast cell stabilization and eosinophil migration, as an antiallergic tablet presumably for the potential treatment of allergies [&lt;ulink linkType="Reference" linkID="1254421"&gt;1254421&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1455826"&gt;1455826&lt;/ulink&gt;]. In May 2013, launch took place in Korea [&lt;ulink linkType="Reference" linkID="1463425"&gt;1463425&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company developed the agent in collaboration with &lt;ulink linkType="Company" linkID="1037556"&gt;Samchundang&lt;/ulink&gt;, &lt;ulink linkType="Company" linkID="21257"&gt;Dong Kook&lt;/ulink&gt;, &lt;ulink linkType="Company" linkID="23350"&gt;Daewon&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="19561"&gt;Sam-A&lt;/ulink&gt;. Each company was to launch it under separate brand names   [&lt;ulink linkType="Reference" linkID="1465901"&gt;1465901&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In December 2011, launch was planned for    May 2012 [&lt;ulink linkType="Reference" linkID="1254421"&gt;1254421&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In April 2011, an open-label, randomized, crossover, single-dose, phase I bio-equivalence study (&lt;ulink linkType="Protocol" linkID="145716"&gt;NCT01897428&lt;/ulink&gt;; HL-BPT-101) to assess the pharmacokinetics of the drug compared to bepotastine besilate in healthy subjects (n = 26) was initiated in South Korea; in July 2013, the trial was completed [&lt;ulink linkType="Reference" linkID="1455826"&gt;1455826&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1004564">Hanlim Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-05-01T00:00:00.000Z</StatusDate><Source id="1463425" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19561">SAMA Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="12">Allergy</Indication><Source id="1465901" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21257">Dong Kook Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="12">Allergy</Indication><Source id="1465901" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037556">SamChunDang Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="12">Allergy</Indication><Source id="1465901" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23350">Daewon Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="12">Allergy</Indication><Source id="1465901" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1004564">Hanlim Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-31T00:00:00.000Z</StatusDate><Source id="1254421" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1004564">Hanlim Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-04-30T00:00:00.000Z</StatusDate><Source id="1455826" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1037556">SamChunDang Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="12">Allergy</Indication><Source id="1465901" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21257">Dong Kook Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="12">Allergy</Indication><Source id="1465901" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23350">Daewon Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="12">Allergy</Indication><Source id="1465901" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19561">SAMA Pharm Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="12">Allergy</Indication><Source id="1465901" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00915"><Name>Histamine H1 receptor</Name><SwissprotNumbers><Swissprot>P30546</Swissprot><Swissprot>P31389</Swissprot><Swissprot>P31390</Swissprot><Swissprot>P35367</Swissprot><Swissprot>P70174</Swissprot><Swissprot>Q9N2B0</Swissprot><Swissprot>Q9N2B1</Swissprot><Swissprot>Q9N2B2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1004564">Hanlim Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="1037556">SamChunDang Pharm Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19561">SAMA Pharm Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21257">Dong Kook Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23350">Daewon Pharm Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1ccnc(c1)[C@H](c2ccc(cc2)Cl)OC3CCN(CC3)CCCC(=O)O</Smiles><Smiles>c1ccc(c(c1)C(=O)O)O.c1ccnc(c1)[C@H](c2ccc(cc2)Cl)OC3CCN(CC3)CCCC(=O)O</Smiles></StructureSmiles><Deals><Deal id="146331" title="Hanlim to codevelop bepotastine salicylate with Samchundang"></Deal><Deal id="146332" title="Hanlim to codevelop bepotastine salicylate with Dong Kook Pharm"></Deal><Deal id="146334" title="Hanlim to codevelop bepotastine salicylate with Daewon"></Deal><Deal id="146335" title="Hanlim to codevelop bepotastine salicylate with Sam-A"></Deal></Deals><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>